Enhanced anti-tumor immune responses and delay of tumor development in human epidermal growth factor receptor 2 mice immunized with an immunostimulatory peptide in poly(D, L-lactic-co-glycolic) acid nanoparticles nanoparticles
2015 (English)In: Breast Cancer Research, ISSN 1465-542X, Vol. 17, no 48Article in journal (Refereed) Published
Introduction Cancer vaccines have the potential to induce curative anti-tumor immune responses and better adjuvants may improve vaccine efficacy. We have previously shown that Hp91, a peptide derived from the B box domain in high-mobility group box protein 1 (HMGB1), acts as potent immune adjuvant. Method In this study, Hp91 was tested as part of a therapeutic vaccine against human epidermal growth factor receptor 2 (HER2) positive breast cancer. Results Free peptide did not significantly augment immune responses but, when delivered in poly(D, L-lactic-co-glycolic) acid nanoparticles (PLGA-NPs), robust activation of dendritic cells (DCs) and increased activation of HER2 specific T cells was observed in vitro. Vaccination of HER2NEU transgenic mice, a mouse breast cancer model that closely mimics the immune modulation and tolerance in some breast cancer patients, with Hp91 loaded PLGA-NPs enhanced the activation of HER2 specific cytotoxic T lymphocyte (CTL) responses, delayed tumor development, and prolonged survival. Conclusion Taken together these findings demonstrate that the delivery of the immunostimulatory peptide Hp91 inside PLGA-NPs enhances the potency of the peptide and efficacy of a breast cancer vaccine.
Place, publisher, year, edition, pages
BioMed Central , 2015. Vol. 17, no 48
IdentifiersURN: urn:nbn:se:liu:diva-117376DOI: 10.1186/s13058-015-0552-9ISI: 000352093600001PubMedID: 25882711OAI: oai:DiVA.org:liu-117376DiVA: diva2:807851
Funding Agencies|US Army Medical Research and Material Command from the National Institutes of Health/NCI [W81XWH-07-1-0412, 5U54CA119335]2015-04-242015-04-242015-04-28